Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Show more

60 First Street, Cambridge, MA, 02141, United States

Biotechnology

Healthcare

Market Cap

120.5M

52 Wk Range

$5.20 - $55.89

Previous Close

$12.80

Open

$13.23

Volume

377,587

Day Range

$12.45 - $13.70

Enterprise Value

72.73M

Cash

92.48M

Avg Qtr Burn

-17.18M

Insider Ownership

4.30%

Institutional Own.

65.74%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KRRO-110 Details Alpha-1 Antitrypsin Deficiency	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KRRO-121 (RNA Editing Oligonucleotide) Details Hyperammonemia, including urea cycle disorders and hepatic encephalopathy	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FX-345 Details Sensorineural hearing loss, Ear disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FX-322 Details Ear disease, Sensorineural hearing loss	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.